Brief: Obseva Announces Additional Efficacy Results For Linzagolix 200 Mg With Add-Back Therapy And Linzagolix 75 Mg Without Abt In Phase 3 Edelweiss 3 Trial In Patients With Moderate-To-Severe Endometriosis-Associated Pain

Obseva SA

22/03/2022 11:45

March 22 (Reuters) - Obseva SA  OBSN.S :
    * OBSEVA ANNOUNCES ADDITIONAL EFFICACY RESULTS FOR
LINZAGOLIX 200
MG WITH ADD-BACK THERAPY (ABT) AND LINZAGOLIX 75 MG WITHOUT ABT
IN THE PHASE 3 EDELWEISS 3 TRIAL IN PATIENTS WITH
MODERATE-TO-SEVERE ENDOMETRIOSIS-ASSOCIATED PAIN
    * OBSEVA SA - RESULTS FROM POST-TREATMENT FOLLOW-UP OF
EDELWEISS 3
ARE EXPECTED IN EARLY 3Q2022
    * OBSEVA SA - RESULTS FROM TREATMENT PHASE OF EXTENSION
STUDY AND
POST-TREATMENT FOLLOW-UP PHASE EXPECTED IN EARLY 3Q2022 AND
4Q2022, RESPECTIVELY
    * OBSEVA SA - REDUCTIONS IN CO-PRIMARY EFFICACY ENDPOINTS,
COMPARED TO PLACEBO OBSERVED FOR BOTH DOSES AFTER 1 & 2 MONTHS
OF TREATMENT, RESPECTIVELY

Source text for Eikon:  ID:nGNX3b9KdF 
Further company coverage:  OBSN.S 

 ((Reuters.Briefs@thomsonreuters.com;))